VRG Therapeutics Overview

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.07M

  • Investors
  • 6

VRG Therapeutics General Information

Description

Developer of a mini-protein technology designed to bring new treatments for poorly managed diseases. The company's technology optimizes peptides of natural origin to create cellular and gene therapy products that treat central nervous system diseases, enabling medical professionals to tackle diseases through mechanisms that conventional biopharmaceutical approaches cannot achieve.

Contact Information

Formerly Known As
Vascular Research Group
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • BioPartner 3, J.H. Oortweg 21
  • 2333 CH Leiden
  • Netherlands
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • BioPartner 3, J.H. Oortweg 21
  • 2333 CH Leiden
  • Netherlands

VRG Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VRG Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 01-Jul-2025 $2.07M Completed Pre-Clinical Trials
7. Later Stage VC Completed Startup
6. Grant 01-Oct-2024 Completed Pre-Clinical Trials
5. Later Stage VC (Series A) 14-Aug-2023 Completed Pre-Clinical Trials
4. Seed Round Completed Pre-Clinical Trials
3. Grant 22-Jul-2021 Completed Pre-Clinical Trials
2. Grant 12-Dec-2019 $1.07M Completed Pre-Clinical Trials
1. Grant 15-Nov-2017 $1.87M Completed Pre-Clinical Trials
To view VRG Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

VRG Therapeutics Patents

VRG Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024502586-A Chlorotoxin derivatives and their uses Active 30-Dec-2020
CA-3203901-A1 Chlorotoxin derivatives and use thereof Active 30-Dec-2020

VRG Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VRG Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Research, Development and Innovation Office Government
Széchenyi Funds Venture Capital Minority
Vascular Venture Venture Capital Minority
National Office for Research, Development and Innovation Corporation
Lief Holdings Corporation Minority
You’re viewing 5 of 6 investors. Get the full list »

VRG Therapeutics FAQs

  • Where is VRG Therapeutics headquartered?

    VRG Therapeutics is headquartered in Leiden, Netherlands.

  • What is the size of VRG Therapeutics?

    VRG Therapeutics has 24 total employees.

  • What industry is VRG Therapeutics in?

    VRG Therapeutics’s primary industry is Biotechnology.

  • Is VRG Therapeutics a private or public company?

    VRG Therapeutics is a Private company.

  • What is VRG Therapeutics’s current revenue?

    The current revenue for VRG Therapeutics is .

  • How much funding has VRG Therapeutics raised over time?

    VRG Therapeutics has raised $11.1M.

  • Who are VRG Therapeutics’s investors?

    National Research, Development and Innovation Office, Széchenyi Funds, Vascular Venture, National Office for Research, Development and Innovation, and Lief Holdings are 5 of 6 investors who have invested in VRG Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process